SCHEMBL2284507

SCHEMBL2284507

CON(C(C)=O)c1ccc(/C=C/C(=O)c2c(O)cc(C)[nH]c2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.53
HTT P42858 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MAPT P10636 3/20 0.45
SLC5A1 P13866 2/20 0.44
SLC5A2 P31639 2/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NFKB1 P19838 1/20 0.41
DPP4 P27487 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
PADI4 Q9UM07 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275775 0.89 LMNA (0.45) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2281141 0.76 LMNA (0.54) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2281145 0.76 LMNA (0.54) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2279826 0.75 LMNA (0.52) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2279822 0.75 LMNA (0.52) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2284564 0.75 LMNA (0.54) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2284568 0.75 LMNA (0.54) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL12374659 0.74 LMNA (0.51) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2284512 0.74 LMNA (0.51) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL12374656 0.74 LMNA (0.53) LMNAHTTSMN1; SMN2NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 LMNA 537/4885HTT 4798/4885SMN1; SMN2 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.